Renal pelvic squamous cell carcinoma is an uncommon and fast-growing cancer that originates in the renal pelvis region or the bordering urothelium. Protheragen has an array of services for the creation of diagnostics and therapeutics specifically for renal pelvic squamous cell carcinoma. Protheragen offers preclinical studies, diagnostic assay creation, and screening of therapeutic agents that are customized to fulfill the requirements of our clients.
Overview of Renal Pelvic Squamous Cell Carcinoma
Renal pelvic squamous cell carcinoma is an uncommon and highly lethal cancer that forms in the renal pelvis, which is the upper section of the ureter that collects the urine before it is transported to the bladder. This form of cancer constitutes between 0.5% to 15% of all cancers in the upper urinary tract and is strongly linked to persistent inflammation and irritation from long-standing kidney stones, recurrent urinary tract infections, and previous surgical therapeutics for renal stones. Because of the vague nature of the clinical symptoms and absence of distinct imaging characteristics, renal pelvic squamous cell carcinoma is typically detected in the late stages, which significantly worsens the prognosis. The median survival time post-surgery is merely 5-7 months, and only 10% of the patients live beyond five years.
Fig.1 A case study of histopathological analysis of renal pelvic squamous cell carcinoma. (Balzer O.,
et al., 2021)
Diagnostics Development for Renal Pelvic Squamous Cell Carcinoma
- Imaging Diagnostics
Due to the lack of extensive clinical imaging and the rarity of renal pelvic squamous cell carcinoma, these cancers tend to be diagnosed later along the progression of the disease, with the assistance of imaging technologies. Ultrasound, X-ray, and CTs are traditionally used to evaluate the kidneys for hydronephrosis or renal calculi. While these modalities aid in visualizing the kidneys, imaging studies by themselves are not sufficient for the diagnosis of renal pelvic squamous cell carcinoma. Stagnant renal pelvic squamous cell carcinoma processes are very complex, and imaging studies may show an inhomogeneous mass or an irregular renal pelvis. These findings, while suggestive of carcinoma, are not definitive.
- Histopathological Diagnostics
Renal pelvic squamous cell carcinoma is diagnosed through histopathological examination. After nephrectomy or nephroureterectomy, renal pelvic tissues are screened for squamous cell carcinoma. The presence of squamous metaplasia and carcinoma is suggested by keratinization, intercellular bridges, and squamous cell-like differentiation. Other immunohistochemical markers, P63 and P40, are also used to tell renal pelvic squamous cell carcinoma apart from other types of urothelial carcinoma./li>
- Biopsy and Molecular Diagnostics
For definitive diagnostic information, renal pelvic biopsies may be performed in patients with nonfunctioning kidneys and recurrent stone disease. Direct histological analysis, which can confirm the presence of squamous cell carcinoma, is possible through these biopsies. In efforts to enable more precise diagnosis and personalized therapeutics, molecular diagnostics, such as assessing genetic markers and tumor mutational profiles, are being studied.
Therapeutics of Renal Pelvic Squamous Cell Carcinoma
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy |
Gemcitabine + Cisplatin |
Gemcitabine inhibits DNA synthesis; Cisplatin causes DNA crosslinking and apoptosis. |
Combination therapy is often used post-surgery for renal pelvic squamous cell carcinoma to reduce tumor burden and prevent recurrence. |
Approved |
| Chemotherapy |
Gemcitabine (Monotherapy) |
Inhibits DNA synthesis, leading to cell death. |
Monotherapy is used when renal function is compromised. |
Approved |
| Chemotherapy |
Cisplatin |
Crosslinks DNA, causing apoptosis. |
Standard chemotherapeutic agent used to treat advanced renal pelvic squamous cell carcinoma. |
Approved |
| Targeted Therapy |
Bevacizumab (Anti-VEGF) |
Inhibits vascular endothelial growth factor (VEGF), blocking blood vessel formation. |
Used to target the tumor's blood supply, potentially beneficial in metastatic renal pelvic squamous cell carcinoma, often combined with chemotherapy. |
Approved |
| Immunotherapy |
Pembrolizumab (PD-1 Inhibitor) |
Blocks PD-1/PD-L1 interaction, enhancing immune response against tumor cells. |
Used for metastatic cases of renal pelvic squamous cell carcinoma, particularly when PD-L1 expression is present, to boost the immune system response. |
Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen offers customized services for renal pelvic squamous cell carcinoma diagnostics and therapeutics development. Our services are tailored to meet the unique needs of each client, providing flexible and innovative solutions for preclinical research. Our team collaborates with clients to design and implement customized research protocols, ensuring that each project is optimized for success.
Disease Models
- N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) Induced Models
- Ptch1 Conditional Knockout Models
- Patient-Derived Tumor Xenograft (PDX) Models
- Cell Line-Derived Xenograft (CDX) Models
Protheragen's diagnostics and therapeutics development services for renal pelvic squamous cell carcinoma are characterized by our commitment to scientific excellence and innovation. Our services feature advanced imaging technologies, comprehensive histopathological evaluations, and the development of targeted therapies. If you are interested in our services, please feel free to contact us.
References
- Balzer, Oliver, et al. "Squamous cell carcinoma of the renal pelvis in a patient with long-term spinal cord injury—a case report." Spinal Cord Series and Cases 7.1 (2021): 102.
- Wu, Junjun, et al. "Primary renal parenchymal squamous cell carcinoma involving the renal pelvis: a case report and review of the literature." Urology Case Reports (2025): 103083.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
